Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in AUD (TTM)9.08m
- Net income in AUD-135.25m
- Incorporated2004
- Employees73.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immutep Ltd | 119.62k | -42.72m | 414.55m | 19.00 | -- | 2.20 | -- | 3,465.57 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
| Opthea Ltd | 191.71k | -338.68m | 769.43m | 5.00 | -- | -- | -- | 4,013.50 | -0.5313 | -0.5313 | 0.0003 | -0.1068 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Mesoblast Ltd | 9.08m | -135.25m | 1.70bn | 73.00 | -- | 2.29 | -- | 186.82 | -0.1347 | -0.1347 | 0.0092 | 0.6473 | 0.0088 | -- | 3.21 | 124,326.00 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 1.91bn | -- | -- | 12.72 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Telix Pharmaceuticals Ltd | 645.68m | 49.19m | 7.43bn | 234.00 | 148.30 | 18.37 | 131.66 | 11.51 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 36.89m | 3.23% |
| M&G Investment Management Ltd.as of 31 Aug 2023 | 27.50m | 2.41% |
| Thorney Investment Group Australia Pty Ltd.as of 27 Sep 2024 | 20.00m | 1.75% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 15.77m | 1.38% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 10.38m | 0.91% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 8.48m | 0.74% |
| Independent Asset Management Pty Ltd.as of 27 Sep 2024 | 6.72m | 0.59% |
| DFA Australia Ltd.as of 30 Sep 2024 | 5.42m | 0.48% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.76m | 0.24% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jul 2024 | 2.62m | 0.23% |
